SHILPA DIWAN: Open Payments
NPI 1942457999 · IRVINE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$737 in 35 payments from 11 companies in 2025. Trend: 2023 $219 · 2024 $443 · 2025 $737
Food & beverage: $737
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 11 | $242 |
| Alkermes, Inc. | 4 | $76 |
| Neurocrine BioSciences, Inc. | 3 | $72 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $67 |
| Supernus Pharmaceuticals, Inc. | 3 | $62 |
| Tris Pharma Inc | 3 | $62 |
| Axsome Therapeutics, Inc. | 2 | $53 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $47 |
| E.R. Squibb & Sons, L.L.C. | 1 | $21 |
| Lundbeck LLC | 1 | $19 |
Products named: VRAYLAR, ARISTADA, INGREZZA, TRINTELLIX, Dyanavel XR, Auvelity, CAPLYTA, REXULTI.
Industry payments across CA — which companies pay providers there.
